Mirum Pharmaceuticals, Inc. - common stock (MIRM) News

Mirum Pharmaceuticals, Inc. - common stock (MIRM): $17.72

0.12 (+0.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MIRM News Items

MIRM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MIRM News Highlights

  • MIRM's 30 day story count now stands at 7.
  • Over the past 13 days, the trend for MIRM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about MIRM are ARCE, DECK and ED.

Latest MIRM News From Around the Web

Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Analysts’ Top Healthcare Picks: Mirum Pharmaceuticals (MIRM)

There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Mirum Pharmaceuticals (MIRM – Research Report) with bullish sentiments. Mirum Pharmaceuticals (MIRM) In a report issued on January 11, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals. The company's shares closed last Friday at $18.74. According to TipRanks.

Christine Brown on TipRanks | January 17, 2022

Mesirow Financial Investment Management, Inc. ...

Investment company Mesirow Financial Investment Management, Inc. (Current Portfolio) buys Green Brick Partners Inc, Cadre Holdings Inc, Identiv Inc, Atlanticus Holdings Corp, Andersons Inc, sells TriState Capital Holdings Inc, The Joint Corp, Mirum Pharmaceuticals Inc, Genasys Inc, CareDx Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mesirow Financial Investment Management, Inc..

Yahoo | January 14, 2022

H.C. Wainwright Keeps a Buy Rating on Mirum Pharmaceuticals (MIRM)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report), with a price target of $64.00. The company's shares closed last Tuesday at $15.92. According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.4% and a 38.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals. Mirum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $57.67.

Brian Anderson on TipRanks | January 12, 2022

Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow

The following slide deck was published by Mirum Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 11, 2022

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

FOSTER CITY, Calif., January 11, 2022--Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

Yahoo | January 11, 2022

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., January 11, 2022--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | January 11, 2022

Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

FOSTER CITY, Calif., January 04, 2022--Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Yahoo | January 4, 2022

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected to Announce Earnings of -$0.06 Per Share

Equities research analysts expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) to report ($0.06) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have provided estimates for Mirum Pharmaceuticals earnings. The lowest EPS estimate is ($2.36) and the highest is $1.66. Mirum Pharmaceuticals reported earnings of ($1.43) per share during the same quarter last year, []

Transcript Daily | December 17, 2021

Mirum Pharmaceuticals Gets The ''Thumbs Up''

No summary available.

Seeking Alpha | December 16, 2021

Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

Business Wire | December 15, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5498 seconds.